Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6KEW7
|
|||
| Drug Name |
YG1699
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Company |
Youngene Therapeutics Shanghai, China
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 1 (SGLT1) | Target Info | Inhibitor | [1] |
| Sodium/glucose cotransporter 2 (SGLT2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Carbohydrate digestion and absorption | |||
| Bile secretion | ||||
| Mineral absorption | ||||
| Pathwhiz Pathway | Lactose Degradation | |||
| Trehalose Degradation | ||||
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Metabolism of carbohydrates | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.